title: Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea.
abstract: OBJECTIVE
  The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC).
  
  
  METHODS
  Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment.
  
  
  RESULTS
  Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progression-free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients (18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot syndrome (9.2%).
  
  
  CONCLUSIONS
  Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.
authors.affiliation: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Min Hee
authors.initials: MH
authors.lastname: Hong
authors.forename: Hyo Song
authors.initials: HS
authors.lastname: Kim
authors.forename: Chan
authors.initials: C
authors.lastname: Kim
authors.forename: Jung Ryun
authors.initials: JR
authors.lastname: Ahn
authors.forename: Hong Jae
authors.initials: HJ
authors.lastname: Chon
authors.forename: Sang-Joon
authors.initials: SJ
authors.lastname: Shin
authors.forename: Joong-Bae
authors.initials: JB
authors.lastname: Ahn
authors.forename: Hyun Cheol
authors.initials: HC
authors.lastname: Chung
authors.forename: Sun Young
authors.initials: SY
authors.lastname: Rha
references.citation: Mol Cancer Ther. 2003 May;2(5):471-8
references.pmid: 12748309
references.citation: Urol Clin North Am. 2003 Nov;30(4):843-52
references.pmid: 14680319
references.citation: Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9
references.pmid: 8855223
references.citation: JAMA. 2006 Jun 7;295(21):2516-24
references.pmid: 16757724
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Cancer Res Treat. 2008 Dec;40(4):211-3
references.pmid: 19688133
references.citation: J Clin Oncol. 2007 Mar 1;25(7):884-96
references.pmid: 17327610
references.citation: Nat Genet. 1994 May;7(1):85-90
references.pmid: 7915601
references.citation: Dis Colon Rectum. 2007 Dec;50(12):2180-7
references.pmid: 17963003
references.citation: J Clin Oncol. 2006 May 10;24(14):2137-50
references.pmid: 16682732
references.citation: Clin Cancer Res. 2008 Jan 1;14(1):8-13
references.pmid: 18172246
references.citation: Cutan Ocul Toxicol. 2008;27(4):311-5
references.pmid: 19037763
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: J Clin Oncol. 2004 Feb 1;22(3):454-63
references.pmid: 14752067